会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 81. 发明授权
    • Sol particle decay protection immunoassay
    • 溶胶颗粒衰减保护免疫测定
    • US5750411A
    • 1998-05-12
    • US656904
    • 1996-06-03
    • Ronald G. Sommer
    • Ronald G. Sommer
    • G01N33/53G01N33/543G01N33/553G01N33/58G01N33/544
    • G01N33/553G01N33/585
    • Disclosed is a method for determining the concentration of an analyte in a liquid test sample. The method involves the use of colloidal sized metal particles, which exhibit a spectral response in the agglomerated state which is detectably different than in their unagglomerated state, which bear specific binding partners for the analyte in question on their surface. The specific binding partner treated colloidal particles are combined in a buffered, aqueous medium with a destabilizer material capable of destabilizing the specific binding partner-colloidal particle conjugates thereby permitting the particles to agglomerate. Also included in the liquid medium is a polymer bearing multiple analyte or analyte analog molecules along its surface which serves to protect the specific binding partner coated metal particles from dissociation by the destabilizing agent. Analyte added to the medium, typically in the form of a fluid test sample, competes for the specific binding partner and thereby decreases the amount of protection afforded by the analyte or analyte analog bearing polymer which permits unprotected colloidal particles to agglomerate and provide a detectable spectral response. The magnitude of the change in spectral response is directly proportional to the concentration of analyte in the fluid test sample.
    • 公开了一种用于测定液体测试样品中分析物浓度的方法。 该方法包括使用胶体大小的金属颗粒,其在附聚状态下显示出可见的不同于其未凝集状态的光谱响应,其在其表面上承载所讨论的分析物的特异性结合配偶体。 将特异性结合配偶体处理的胶体颗粒在缓冲的含水介质中与能够使特异性结合配偶体 - 胶体粒子共轭物不稳定的去稳定剂材料组合,从而允许颗粒附聚。 还包括在液体介质中的是具有沿其表面的多个分析物或分析物类似物分子的聚合物,其用于保护特异性结合配偶体涂覆的金属颗粒免受不稳定剂的分解。 通常以流体测试样品的形式添加到培养基中的分析物竞争特异性结合配偶体,从而减少被分析物或分析物模拟轴承聚合物提供的保护的量,其允许未受保护的胶体颗粒附聚并提供可检测的光谱 响应。 光谱响应变化的大小与流体测试样品中分析物的浓度成正比。
    • 82. 发明授权
    • Analytical reagent particle with covalently-bound enzyme
    • 具有共价结合酶的分析试剂颗粒
    • US5738986A
    • 1998-04-14
    • US730966
    • 1996-10-16
    • Kurt G. I. Nilsson
    • Kurt G. I. Nilsson
    • G01N33/543G01N33/58G01N33/53
    • G01N33/54313G01N33/581G01N33/585Y10S436/829
    • The invention relates to a reagent consisting of at least one enzyme and at least one other substance, which are covalently or noncovalently bound to a particle, which is smaller than or is equal to 1000 Angstrom in diameter. The invention also relates to method and use of the reagent for determination or studies of a cell or a virus or another component in a sample. According to the invention, these determinations are made with for example some ELISA-technique (competitive, sandwich, etc.), employing the reagent preferrably in the form of a suspension in buffered water, instead of and in the same way as described for soluble enzyme conjugates. The substance can be an antibody, a lectin, avidin or an antigen, the enzyme can be for example peroxidase, alkaline phosphatase, and the particle can be an inorganic or an organic polymeric compound or a combination thereof, as, for example, tresyl-activated glycerylpropyl-silica.
    • 本发明涉及由至少一种酶和至少一种其它物质组成的试剂,其与颗粒共价或非共价结合,其直径小于或等于1000埃。 本发明还涉及用于测定或研究样品中的细胞或病毒或其它成分的试剂的方法和用途。 根据本发明,这些测定是用例如一些ELISA技术(竞争性,夹心等)进行的,使用试剂优选以缓冲水中的悬浮液的形式,而不是以与可溶性的相同的方式 酶缀合物。 该物质可以是抗体,凝集素,抗生物素蛋白或抗原,酶可以是例如过氧化物酶,碱性磷酸酶,并且该颗粒可以是无机或有机聚合物或其组合,例如, 活化甘油基丙基二氧化硅。
    • 85. 发明授权
    • Method for depositing metal particles on a marker
    • 将金属颗粒沉积在标记上的方法
    • US5674755A
    • 1997-10-07
    • US467655
    • 1995-06-06
    • Marcus J. M. NoppeFrank J. Konings
    • Marcus J. M. NoppeFrank J. Konings
    • G01N33/532G01N33/553G01N33/58G03C5/58G01N33/533G03C5/30
    • G03C5/58G01N33/532G01N33/553G01N33/585
    • An improved method for depositing metal particles on a marker which catalyzes the reduction of metal ions from a physical developer comprising a solution of metal ions, a molar excess of complexant in respect to the metal ions and a reducing agent. Said method being preferably employed for the detection of one or more components of an aggregate formed between a least one specific binding agent and its corresponding bindable substance by labelling at least one component of said aggregate with a marker and contacting said aggregate with a physical developer, whereby under influence of the marker a metal particle is formed which can be detected. Further the invention also relates to solutions and test-kits adapted for carrying out the above mentioned method.
    • 一种用于在标记上沉积金属颗粒的改进方法,该方法催化从物理显影剂中还原金属离子,所述物理显影剂包括金属离子溶液,相对于金属离子摩尔过量的络合物和还原剂。 所述方法优选用于通过用标记物标记所述骨料的至少一种组分并将所述聚集体与物理显影剂接触来检测形成在至少一种特异性结合剂和其相应的可结合物质之间的聚集体的一种或多种组分, 由此在标记的影响下形成可以检测到的金属颗粒。 此外,本发明还涉及适于实施上述方法的溶液和试剂盒。
    • 87. 发明授权
    • Assay of blood or other biologic samples for target analytes
    • 测定目标分析物的血液或其他生物样品
    • US5635362A
    • 1997-06-03
    • US247336
    • 1994-05-23
    • Robert A. LevineStephen C. WardlawRodolfo R. RodriguezAdrien P. MalickAlvydas J. Ozinskas
    • Robert A. LevineStephen C. WardlawRodolfo R. RodriguezAdrien P. MalickAlvydas J. Ozinskas
    • G01N33/543B01L3/14G01N33/49G01N33/537G01N33/569G01N33/58G01N33/558
    • B01L3/5021G01N33/491G01N33/5375G01N33/56972G01N33/585Y10S435/81Y10S435/967Y10S435/971Y10S435/973Y10S436/805Y10S436/81Y10S436/824Y10S436/829Y10T436/111666
    • A patient's health may be diagnosed by centrifuging blood samples in a transparent tube, which tube contains one or more bodies or groups of bodies such as floats, inserts, liposomes, or plastic beads of different densities. Each density-defined body carries analyte-capture binding materials such as antigens or antibodies, which are specific to an epitope, or other specific high affinity binding site on a target analyte which target analyte may be in the blood or other sample being tested; and the level of which analyte is indicative of the patient's health. At least one labeled binding material which is also specific to an epitope, or other specific high affinity binding site on the target analyte is added to the sample so as to form labeled binding material/analyte/body complexes in the sample. Upon centrifugation, the complexes will settle out in different areas in the tube according to the respective density of the body or bodies; and the degree of label emission of the complex layers can enable qualitative and/or quantitative analyses of the sample to be made. Unbound labeled binding materials will be separated from the complexed layers by the washing action of ascending or descending components of the sample during the centrifugation step. Unbound labeled binding material will thus not interfere with the analysis.
    • 可以通过将透明管中的血液样品离心来诊断患者的健康,该管包含一个或多个不同密度的浮体,插入物,脂质体或塑料珠的主体或组。 每个密度定义的身体携带分析物 - 捕获结合材料,例如抗原或抗体,其对靶分析物是特异性的,或靶分析物上的其它特异性高亲和力结合位点,其目标分析物可能在待测试的血液或其他样品中; 并且其分析物的水平表示患者的健康。 将至少一种对靶分析物上的表位或其他特异性高亲和力结合位点特异性的标记结合物质加入到样品中,以便在样品中形成标记的结合材料/分析物/身体复合物。 离心后,复合物将根据身体或身体的相应密度沉淀在管中的不同区域; 并且复合层的标签发射程度可以使得要进行样品的定性和/或定量分析。 通过在离心步骤期间样品的上升或下降组分的洗涤作用,未结合的标记结合材料将从复合层分离。 因此,未结合的标签结合材料不会影响分析。